Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 14, Issue 4, 2008, Pages 273-280

  Merims, Doron ^a   Giladi, Nir ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Dopamine agonist; Dopamine dysregulation syndrome; Gambling; l Dopa; Parkinson's disease

Indexed keywords

ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LAMOTRIGINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE;

ADDICTION; BEHAVIOR DISORDER; BINGE EATING DISORDER; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; COMPULSION; COMPULSIVE BUYING; COMPULSIVE SHOPPING; DOPAMINE DYSREGULATION SYNDROME; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC TRANSMISSION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; EATING DISORDER; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; INTERNET ADDICTION; OBSESSIVE COMPULSIVE DISORDER; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; REWARD; RISK FACTOR; SEXUAL DEVIATION; SHOPPING; SIDE EFFECT; WEIGHT GAIN;

ANTIPARKINSON AGENTS; BEHAVIORAL SYMPTOMS; DOPAMINE; GAMBLING; HUMANS; LEVODOPA; PARKINSON DISEASE; SUBSTANCE-RELATED DISORDERS;

EID: 44349131102     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2007.09.007     Document Type: Review

References (78)

1. Spanagel R., and Heilig M. Addiction and its brain science. Addiction 100 12 (2005) 1813-1822 Review
2. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Rev 49 1 (2005) 77-105 Review
3. Bressan R.A., and Crippa J.A. The role of dopamine in reward and pleasure behaviour-review of data from preclinical research. Acta Psychiatr Scand Suppl 427 (2005) 14-21 Review
4. Koepp M.J., Gunn R.N., Lawrence A.D., Cunningham V.J., Dagher A., Jones T., et al. Evidence for striatal dopamine release during a video game. Nature 393 (1998) 266-268
5. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 5335 (1997) 52-58
6. Robinson T.E., and Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 Suppl. 2 (2000) S91-S117 Review
7. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 2 (2001) 97-129 Review
8. Chen G., Kittler J.T., Moss S.J., and Yan Z. Dopamine D3 receptors regulate GABA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J Neurosci 26 9 (2006) 2513-2521
9. Xi Z.X., Gilbert J., Campos A.C., Kline N., Ashby Jr. C.R., Hagan J.J., et al. Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berlin) 176 1 (2004) 57-65
10. Pak A.C., Ashby C.R., Heidbreder C.A., Pilla M., Gilbert J., Xi Z.X., et al. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 31 (2006) 1-18
11. Hiroi N., and Agatsuma S. Genetic susceptibility to substance dependence. Mol Psychiatry 10 4 (2005) 336-344 Review
12. Kronenberg M.F., Menzel H.J., Ebersbach G., Wenning G.K., Luginger E., Gollner M., et al. Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. Eur J Hum Genet 7 3 (1999) 397-400
13. Dulawa S.C., Grandy D.K., Low M.J., Paulus M.P., and Geyer M.A. Dopamine D4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19 21 (1999) 9550-9556
14. Pogorelov V.M., Rodriguiz R.M., Insco M.L., Caron M.G., and Wetsel W.C. Novelty seeking and stereotypic activation of behavior in mice with disruption of the Dat1 gene. Neuropsychopharmacology 30 10 (2005) 1818-1831
15. Goto Y., and Grace A.A. Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 8 6 (2005) 805-812
16. Evans A.H., Pavese N., Lawrence A.D., Tai Y.F., Appel S., Doder M., et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 59 5 (2006) 852-858
17. Poewe W., Gerstenbrand F., Ransmayr G., and Plorer S. Premorbid personality of Parkinson patients. J Neural Transm Suppl 19 (1983) 215-224
18. Hubble J.P., Venkatesh R., Hassanein R.E., Gray C., and Koller W.C. Personality and depression in Parkinson's disease. J Nerv Ment Dis 181 11 (1993) 657-662
19. Menza M.A., Forman N.E., Goldstein H.S., and Golbe L.I. Parkinson's disease, personality, and dopamine. J Neuropsychiatry Clin Neurosci 2 3 (1990) 282-287
20. Menza M.A., Golbe L.I., Cody R.A., and Forman N.E. Dopamine-related personality traits in Parkinson's disease. Neurology 43 3 Part 1 (1993) 505-508
21. Bell I.R., Amend D., Kaszniak A.W., Schwartz G.E., Peterson J.M., Stini W.A., et al. Trait shyness in the elderly: evidence for an association with Parkinson's disease in family members and biochemical correlates. J Geriatr Psychiatry Neurol 8 1 (1995) 16-22
22. Menza M.A., Mark M.H., Burn D.J., and Brooks D.J. Personality correlates of [18F]dopa striatal uptake: results of positron-emission tomography in Parkinson's disease. J Neuropsychiatry Clin Neurosci 7 2 (1995) 176-179
23. Fujii C., Harada S., Ohkoshi N., Hayashi A., and Yoshizawa K. Cross-cultural traits for personality of patients with Parkinson's disease in Japan. Am J Med Genet 96 1 (2000) 1-3
24. Paulson G.W., and Dadmehr N. Is there a premorbid personality typical for Parkinson's disease?. Neurology 41 5 Suppl. 2 (1991) 73-76 Review
25. Jimenez-Jimenez F.J., Mateo D., and Gimenez-Roldan S. Premorbid smoking, alcohol consumption, and coffee drinking habits in Parkinson's disease: a case-control study. Mov Disord 7 4 (1992) 339-344
26. Evans A.H., Lawrence A.D., Potts J., MacGregor L., Katzenschlager R., Shaw K., et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry 77 3 (2006) 317-321
27. Pezzella F.R., Di Rezze S., Chianese M., Fabbrini G., Vanacore N., Colosimo C., et al. Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire. Neurol Sci 24 3 (2003) 205-206
28. Pezzella F.R., Colosimo C., Vanacore N., Di Rezze S., Chianese M., Fabbrini G., et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 20 1 (2005) 77-81
29. Giovannoni G., O'Sullivan J.D., Turner K., Manson A.J., and Lees A.J. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 4 (2000) 423-428
30. Lawrence A.D., Evans A.H., and Lees A.J. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?. Lancet Neurol 2 10 (2003) 595-604 Review
31. Bearn J., Evans A., Kelleher M., Turner K., and Lees A. Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study. Drug Alcohol Depend 76 3 (2004) 305-310
32. Giladi N., Weitzman N., Schreiber S., Shabtai H., and Peretz C. New-onset heightened interest or drive for gambling, eating, shopping or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 21 (2007) 501-506
33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. 2000.
34. Molina J.A., Sainz-Artiga M.J., Fraile A., Jimenez-Jimenez F.J., Villanueva C., Orti-Pareja M., et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment?. Mov Disord 15 5 (2000) 869-872
35. Seedat S., Kesler S., Niehaus D.J., and Stein D.J. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 11 4 (2000) 185-186
36. Gschwandtner U., Aston J., Renaud S., and Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 24 3 (2001) 170-172
37. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 3 (2003) 422-423
38. Avanzi M., Uber E., and Bonfa F. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease. Neurol Sci 25 2 (2004) 98-101
39. Dodd M.L., Klos K.J., Bower J.H., Geda Y.E., Josephs K.A., and Ahlskog J.E. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 9 (2005) 1377-1381
40. Szarfman A., Doraiswamy P.M., Tonning J.M., and Levine J.G. Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol 63 2 (2006) 299-300
41. Imamura A., Uitti R.J., and Wszolek Z.K. Dopamine agonist therapy for Parkinson's disease and pathological gambling. Parkinsonism Relat Disord 12 8 (2006) 506-508
42. Grosset K.A., Macphee G., Pal G., Stewart D., Watt A., Davie J., et al. DAs and pathological gambling. Parkinsonism Relat Disord 13 4 (2007) 259
43. Bancroft J., and Vukadinovic Z. Sexual addiction, sexual compulsivity, sexual impulsivity, or what? Toward a theoretical model. J Sex Res 41 3 (2004) 225-234
44. Kalichman S.C., and Rompa D. The Sexual Compulsivity Scale: further development and use with HIV-positive persons. J Pers Assess 76 3 (2001) 379-395
45. Dodge B., Reece M., Cole S.L., and Sandfort T.G. Sexual compulsivity among heterosexual college students. J Sex Res 41 4 (2004) 343-350
46. Vogel H.P., and Schiffer R. Hypersexuality-a complication of dopaminergic therapy in Parkinson's disease. Pharmacopsychiatria 16 4 (1983) 107-110
47. Uitti R.J., Tanner C.M., Rajput A.H., Goetz C.G., Klawans H.L., and Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 5 (1989) 375-383
48. O'Sullivan J.D., and Hughes A.J. Apomorphine-induced penile erections in Parkinson's disease. Mov Disord 13 3 (1998) 536-539
49. Evans A.H., and Lees A.J. Dopamine dysregulation syndrome in Parkinson's disease. Curr Opin Neurol 17 4 (2004) 393-398 Review
50. Klos K.J., Bower J.H., Josephs K.A., Matsumoto J.Y., and Ahlskog J.E. Pathological hypersexuality predominantly linked to adjuvant DA therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 6 (2005) 381-386
51. Riley D.E. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol 25 4 (2002) 234-237
52. Harvey N.S. Serial cognitive profiles in levodopa-induced hypersexuality. Br J Psychiatry 153 (1988) 833-836
53. Langstrom N., and Hanson R.K. High rates of sexual behavior in the general population: correlates and predictors. Arch Sex Behav 35 1 (2006) 37-52
54. Grabowska-Grzyb A., Naganska E., and Wolanczyk T. Hypersexuality in two patients with epilepsy treated with lamotrigine. Epilepsy Behav 8 3 (2006) 663-665 Epub 2006
55. Shapiro M.A., Chang Y.L., Munson S.K., Okun M.S., and Fernandez H.H. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord 12 6 (2006) 392-395
56. Lejoyeux M., Tassain V., Solomon J., and Ades J. Study of compulsive buying in depressed patients. J Clin Psychiatry 58 4 (1997) 169-173
57. Lejoyeux M., Bailly F., Moula H., Loi S., and Ades J. Study of compulsive buying in patients presenting obsessive-compulsive disorder. Compr Psychiatry 46 2 (2005) 105-110
58. Maia A.F., Pinto A.S., Barbosa E.R., Menezes P.R., and Miguel E.C. Obsessive-compulsive symptoms, obsessive-compulsive disorder and related disorder in Parkinson's disease. J Neuropsychiatry Clin Neurosci 15 3 (2003) 371-374
59. Nirenberg M.J., and Waters C. Compulsive eating and weight gain related to DA use. Mov Disord 21 4 (2005) 524-529
60. Barichella M., Marczewska A.M., Mariani C., Landi A., Vairo A., and Pezzoli G. Body weight gain rate in patients with Parkinson's disease and deep brain stimulation. Mov Disord 18 11 (2003) 1337-1340
61. Macia F., Perlemoine C., Coman I., Guehl D., Burbaud P., Cuny E., et al. Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight. Mov Disord 19 2 (2004) 206-212
62. Tuite P.J., Maxwell R.E., Ikramuddin S., Kotz C.M., Billington C.J., Laseski M.A., et al. Weight and body mass index in Parkinson's disease patients after deep brain stimulation surgery. Parkinsonism Relat Disord 11 4 (2005) 247-252
63. Novakova L., Ruzicka E., Jech R., Serranova T., Dusek P., and Urgosik D. Increase in body weight is a non-motor side effect of deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neuro Endocrinol Lett 28 1 (2007) 21-25
64. Kostic V., Przedborski S., Flaster E., and Sternic N. Early development of levodopa induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41 2 (1991) 202-205
65. Sossi V., de la Fuente-Fernandez R., Schulzer M., Adams J., and Stoessl J. Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. Brain 129 4 (2006) 1050-1058
66. Witjas T., Baunez C., Henry J.M., Delfini M., Regis J., Cherif A.A., et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 20 8 (2005) 1052-1055
67. Morgan J.C., diDonato C.J., Iyer S.S., Jenkins P.D., Smith J.R., and Sethi K.D. Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Mov Disord 21 2 (2006) 283-285
68. Melamed E., Zoldan J., Galili-Mosberg R., Ziv I., and Djaldetti R. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa. J Neural Transm Suppl 56 (1999) 173-183 Review
69. Maricle R.A., Nutt J.G., Valentine R.J., and Carter J.H. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson's disease: a double-blind, placebo-controlled study. Neurology 45 9 (1995) 1757-1760
70. Calne S. Nursing care of patients with idiopathic parkinsonism. Nurs Times 90 24 (1994) 38-39
71. Witjas T., Kaphan E., Azulay J.P., Blin O., Ceccaldi M., Pouget J., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59 3 (2002) 408-413
72. Tack E., De Cuypere G., Jannes C., and Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 78 3 (1988) 356-360
73. Merims D., Galili-Mosberg R., and Melamed E. Is there addiction to levodopa in patients with Parkinson's disease?. Mov Disord 15 5 (2000) 1014-1016
74. Borek L.L., and Friedman J.H. Levodopa addiction in idiopathic Parkinson disease. Neurology 65 9 (2005) 1508
75. Priebe S. Levodopa dependence: a case report. Pharmacopsychiatry 17 (1984) 109-110
76. Nausieda P.A. Sinemet "abusers". Clin Neuropharmacol 8 (1985) 318-327
77. Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2006 [Epub ahead of print].
78. Ardouin C., Voon V., Worbe Y., Abouazar N., Czernecki V., Hosseini H., et al. Pathological gambling in Parkinson's disease improves by chronic subthalamic nucleus stimulation. Mov Disord 21 11 (2006) 1941-1946